Prostate cancer is the fourth most commonly diagnosed cancer worldwide, with approximately 1.4 million new cases, and is more commonly diagnosed in developed countries. To combat the disease, advanced biomarkers are constantly in development. Even though patients with prostate cancer have improved overall survival, from a global perspective, this is a disease that requires attention in terms of better diagnostic and treatment modalities, especially in the metastatic setting. This activity describes tissue-based biomarkers useful in clinical practice to help determine risk stratification at critical decision points in prostate cancer, which will help determine the relative need for a re-biopsy or further intervention, thus aiding physicians and patients in personalizing care for their disease.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/144431
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
Nursing: 2.0 hours
Pharmacy: 2.0 hours - MOC Credit Details: ABS - 2.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 2.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 2.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 2.0 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: General Surgery, Geriatric Medicine, Internal Medicine, Male Genital, Medical Oncology, Molecular Genetic Pathology, Urinary Tract